loading
Heron Therapeutics Inc stock is traded at $1.815, with a volume of 470.56K. It is up +1.97% in the last 24 hours and down -14.39% over the past month. Heron Therapeutics Inc is a commercial-stage biotechnology company. It is focused on improving the lives of patients by developing treatments that address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
See More
Previous Close:
$1.78
Open:
$1.8
24h Volume:
470.56K
Relative Volume:
0.24
Market Cap:
$269.97M
Revenue:
$127.04M
Net Income/Loss:
$-110.56M
P/E Ratio:
-1.5513
EPS:
-1.17
Net Cash Flow:
$-60.33M
1W Performance:
-4.97%
1M Performance:
-14.39%
6M Performance:
-30.46%
1Y Performance:
+141.84%
1-Day Range:
Value
$1.77
$1.85
1-Week Range:
Value
$1.70
$1.885
52-Week Range:
Value
$0.50
$3.93

Heron Therapeutics Inc Stock (HRTX) Company Profile

Name
Name
Heron Therapeutics Inc
Name
Phone
(858) 251-4400
Name
Address
4242 CAMPUS POINT COURT, SUITE 200, SAN DIEGO, CA
Name
Employee
126
Name
Twitter
Name
Next Earnings Date
2024-11-12
Name
Latest SEC Filings
Name
HRTX's Discussions on Twitter

Heron Therapeutics Inc Stock (HRTX) Upgrades & Downgrades

Date Action Analyst Rating Change
May-27-20 Initiated Guggenheim Buy
Feb-20-20 Reiterated Needham Buy
Jan-16-19 Reiterated Needham Buy
Apr-05-18 Initiated Evercore ISI Outperform
Mar-19-18 Reiterated Mizuho Buy
Mar-01-18 Reiterated Needham Buy
Jan-03-18 Initiated Leerink Partners Outperform
Sep-27-17 Initiated Northland Capital Outperform
Feb-27-17 Initiated Needham Buy
Oct-26-16 Initiated Aegis Capital Buy
Sep-06-16 Resumed Lake Street Buy
May-03-16 Initiated Cantor Fitzgerald Buy
Dec-10-15 Initiated Lake Street Buy
Sep-23-15 Reiterated Leerink Partners Outperform
Sep-02-15 Initiated BofA/Merrill Buy
Aug-03-15 Reiterated Brean Capital Buy
Jun-30-15 Reiterated JMP Securities Mkt Outperform
Jun-19-15 Reiterated Leerink Partners Outperform
Aug-07-14 Initiated Noble Financial Buy
View All

Heron Therapeutics Inc Stock (HRTX) Latest News

pulisher
Oct 31, 2024

Bunion Market Forecasted to Surge in Coming Years, 2024-2034 Analysis by DelveInsight | Heron Therapeutics, Lotus Clinical Research, Cali Pharma, Grünenthal GmbH, Pacira Pharma, Inc, Mallinckrodt - The Globe and Mail

Oct 31, 2024
pulisher
Oct 29, 2024

Heron Therapeutics to Report Third Quarter 2024 Financial Results On Tuesday, November 12, 2024 - Longview News-Journal

Oct 29, 2024
pulisher
Oct 26, 2024

SG Americas Securities LLC Cuts Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Oct 26, 2024
pulisher
Oct 21, 2024

Antinauseants Market Insights, Forecast to 2031Heron - openPR

Oct 21, 2024
pulisher
Oct 20, 2024

The Manufacturers Life Insurance Company Acquires 6,328 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Oct 20, 2024
pulisher
Oct 16, 2024

Heron Therapeutics, Inc. (NASDAQ:HRTX) Short Interest Update - MarketBeat

Oct 16, 2024
pulisher
Oct 15, 2024

Heron Therapeutics Inc (HRTX) deserves deeper analysis - US Post News

Oct 15, 2024
pulisher
Oct 14, 2024

Investor’s Toolkit: Key Ratios for Assessing Heron Therapeutics Inc (HRTX)’s Performance - The Dwinnex

Oct 14, 2024
pulisher
Oct 12, 2024

Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Millennium Management LLC - Defense World

Oct 12, 2024
pulisher
Oct 11, 2024

Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Bought by Congress Park Capital LLC - MarketBeat

Oct 11, 2024
pulisher
Oct 10, 2024

Heron Therapeutics Reaffirms Availability and Ample Supply of CINVANTI®, SUSTOL®, and APONVIE® as Alternatives During the Potential Shortage of Intravenous Fluids - The Malaysian Reserve

Oct 10, 2024
pulisher
Oct 09, 2024

Its Stock Has Paid Off Big Time For Heron Therapeutics Inc - SETE News

Oct 09, 2024
pulisher
Oct 09, 2024

AQR Capital Management LLC Raises Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat

Oct 09, 2024
pulisher
Oct 08, 2024

Heron Therapeutics Inc Inc. (HRTX) Price Performance: The Role of Supply and Demand - The InvestChronicle

Oct 08, 2024
pulisher
Oct 08, 2024

Can you now get a good deal on Heron Therapeutics Inc’s shares? - US Post News

Oct 08, 2024
pulisher
Oct 06, 2024

Squarepoint Ops LLC Purchases 286,160 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat

Oct 06, 2024
pulisher
Oct 03, 2024

Buying Buzz: Heron Therapeutics Inc [HRTX] EVP, Chief Development Officer Forbes William P purchases 25,000 shares of the company – Knox Daily - Knox Daily

Oct 03, 2024
pulisher
Oct 03, 2024

HRTX’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle

Oct 03, 2024
pulisher
Oct 03, 2024

When Can We Expect A Profit From Heron Therapeutics, Inc. (NASDAQ:HRTX)? - Simply Wall St

Oct 03, 2024
pulisher
Oct 02, 2024

Get in on Heron Therapeutics Inc’s (HRTX) buy-in window today! - SETE News

Oct 02, 2024
pulisher
Oct 02, 2024

Heron Therapeutics, Inc.'s (NASDAQ:HRTX) Path To Profitability - Yahoo Finance

Oct 02, 2024
pulisher
Oct 01, 2024

Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Acquired by Marshall Wace LLP - Defense World

Oct 01, 2024
pulisher
Oct 01, 2024

Heron Therapeutics Inc’s results are impressive - US Post News

Oct 01, 2024
pulisher
Oct 01, 2024

Marshall Wace LLP Boosts Holdings in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat

Oct 01, 2024
pulisher
Sep 30, 2024

Market Momentum Report: Heron Therapeutics Inc (HRTX)’s Negative Close at 1.99 - The Dwinnex

Sep 30, 2024
pulisher
Sep 29, 2024

Clearline Capital LP Sells 1,280,938 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat

Sep 29, 2024
pulisher
Sep 26, 2024

Heron gains on FDA nod for new Zynrelef application - MSN

Sep 26, 2024
pulisher
Sep 26, 2024

Renaissance Technologies LLC Reduces Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Sep 26, 2024
pulisher
Sep 26, 2024

Heron Therapeutics Inc [NASDAQ: HRTX] Sees Decrease in Stock Value - Knox Daily

Sep 26, 2024
pulisher
Sep 26, 2024

Renaissance Technologies LLC Lowers Stock Position in Heron Therapeutics, Inc. (NASDAQ:HRTX) - MarketBeat

Sep 26, 2024
pulisher
Sep 25, 2024

Heron Therapeutics’ (HRTX) Buy Rating Reiterated at Needham & Company LLC - Defense World

Sep 25, 2024
pulisher
Sep 25, 2024

Needham & Company LLC Reaffirms "Buy" Rating for Heron Therapeutics (NASDAQ:HRTX) - MarketBeat

Sep 25, 2024
pulisher
Sep 25, 2024

Adversity is less terrifying than hope: Heron Therapeutics Inc (HRTX) - SETE News

Sep 25, 2024
pulisher
Sep 25, 2024

Heron stock gains on FDA nod for Zynrelef method (NASDAQ:HRTX) - Seeking Alpha

Sep 25, 2024
pulisher
Sep 25, 2024

Heron Therapeutics Announces FDA Approval of the Prior Approval Supplement Application for ZYNRELEF® Vial Access Needle ("VAN") - PR Newswire

Sep 25, 2024
pulisher
Sep 25, 2024

Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Bought by Rhumbline Advisers - Defense World

Sep 25, 2024
pulisher
Sep 24, 2024

Heron Therapeutics Inc (HRTX) stock on the rise: An overview - US Post News

Sep 24, 2024
pulisher
Sep 21, 2024

Wealth Alliance Has $112,000 Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Sep 21, 2024
pulisher
Sep 21, 2024

Acadian Asset Management LLC Makes New Investment in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Sep 21, 2024
pulisher
Sep 20, 2024

E Fund Management Co. Ltd. Acquires New Shares in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Sep 20, 2024
pulisher
Sep 20, 2024

Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Orchard Capital Management LLC - Defense World

Sep 20, 2024
pulisher
Sep 19, 2024

Bank of New York Mellon Corp Purchases 113,655 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Pekin Hardy Strauss Inc. Has $88,000 Stake in Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Sep 19, 2024
pulisher
Sep 19, 2024

Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Purchased by Richmond Brothers Inc. - Defense World

Sep 19, 2024
pulisher
Sep 18, 2024

Monitoring Heron Therapeutics Inc (HRTX) after recent insider movements - Knox Daily

Sep 18, 2024
pulisher
Sep 17, 2024

Heron Therapeutics, Inc. (NASDAQ:HRTX) Shares Sold by Principal Financial Group Inc. - Defense World

Sep 17, 2024
pulisher
Sep 17, 2024

Heron Therapeutics Inc (HRTX) stock: A year of ups and downs - US Post News

Sep 17, 2024
pulisher
Sep 17, 2024

Chemotherapy Induced Nausea and Vomiting Treatment Market is Set to Reach US$ 12,688.0 Million by 2034 | Fact.MR - GlobeNewswire Inc.

Sep 17, 2024
pulisher
Sep 16, 2024

Holdings of Heron Therapeutics Inc (HRTX) are aligned with the stars - SETE News

Sep 16, 2024
pulisher
Sep 16, 2024

Market Highlights: Heron Therapeutics Inc (HRTX) Ends on a High Note at 1.87 - The Dwinnex

Sep 16, 2024
pulisher
Sep 14, 2024

Headlands Technologies LLC Acquires 79,609 Shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) - Defense World

Sep 14, 2024

Heron Therapeutics Inc Stock (HRTX) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading

Heron Therapeutics Inc Stock (HRTX) Insider Trading

Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total
Forbes William P
EVP, Chief Development Officer
Nov 16 '23
Buy
0.94
50,000
46,995
54,000
Collard Craig A
Chief Executive Officer
Nov 16 '23
Buy
0.92
150,000
137,970
186,496
Duarte Ira
EVP, Chief Financial Officer
Nov 16 '23
Buy
0.89
85,000
75,599
85,000
$22.66
price up icon 0.80%
$75.22
price down icon 1.25%
$372.48
price down icon 0.03%
$54.26
price down icon 0.74%
$207.51
price up icon 1.32%
$108.16
price down icon 3.03%
Cap:     |  Volume (24h):